The degree of risk reduction depended on the number of prescriptions written
A cohort study by British scientists found that use of phosphodiesterase type 5 inhibitors, which are used to treat erectile dysfunction, was associated with an 18 percent reduction in the risk of Alzheimer’s disease. Notably, disease risk estimates depended on the number of prescriptions filled. Study published In the magazine Neurology.
Although there has been great progress in the treatment of Alzheimer’s disease recently due to the development of monoclonal antibodies targeting amyloid-β plaques, there is a need for effective methods to prevent this form of dementia. Thus, some scientists have suggested that phosphodiesterase type 5 inhibitors, for example, sildenafil (trade name Viagra), may be suitable for this role. Sildenafil increases the level of cyclic guanosine monophosphate, whose level reduced in brain cells of people with Alzheimer’s disease.
These results have led to several studies of phosphodiesterase type 5 inhibitors in animal models that demonstrated possible neuroprotective effects of the drug, but in humans these effects remain largely unproven.
Ruth Brauer and colleagues at University College London conducted a study using IQ VIA health survey data with data from the Health Improvement Network (THIN) database. The study included 269,725 men, with a mean age at cohort entry of 58.5 years and a median follow-up of 5.1 years.
Over 1,309,205 person-years of follow-up, 1,119 people were newly diagnosed with Alzheimer’s disease. The scientists found that starting a phosphodiesterase type 5 inhibitor was associated with an 18 percent lower risk of developing Alzheimer’s disease compared to those not taking it.
In addition, an analysis summing the total number of prescriptions for study drugs found that the relative risk of developing Alzheimer’s disease in patients with 21 to 50 prescriptions was 0.56, and in patients with more than 50 prescriptions it was 0.65. Fewer prescriptions were not associated with a reduced risk. The greatest positive effect was observed during one year of observation of patients; by the third year it noticeably weakened.
The results of this large population-based study suggest that use of phosphodiesterase type 5 inhibitors may be associated with a reduced risk of developing Alzheimer’s disease. However, randomized controlled trials are needed to confirm these findings.
At different times, Viagra has had a variety of effects on the body. So, we talked about the fact that with the help of Viagra they propose to expel stem cells from the bone marrow.
2024-02-08 12:02:00
#Viagra #reduced #risk #developing #Alzheimers #disease #percent
